These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 35367476)

  • 1. Targeted nanomedicine in cisplatin-based cancer therapeutics.
    Han Y; Wen P; Li J; Kataoka K
    J Control Release; 2022 May; 345():709-720. PubMed ID: 35367476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicines Targeting the Tumor Microenvironment.
    Tong R; Langer R
    Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
    Qin SY; Zhang AQ; Zhang XZ
    Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
    Tracey SR; Smyth P; Barelle CJ; Scott CJ
    Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DePEGylation strategies to increase cancer nanomedicine efficacy.
    Kong L; Campbell F; Kros A
    Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel nanomedicines to overcome cancer multidrug resistance.
    Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
    Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine Tumor Targeting.
    Lammers T
    Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
    Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
    AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle formulations of cisplatin for cancer therapy.
    Duan X; He C; Kron SJ; Lin W
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Sep; 8(5):776-91. PubMed ID: 26848041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
    Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
    Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial prospects of nano-targeted chemoimmunotherapy.
    Da Silva CG; Rueda F; Löwik CW; Ossendorp F; Cruz LJ
    Biomaterials; 2016 Mar; 83():308-20. PubMed ID: 26796043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment.
    Gao Q; Feng J; Liu W; Wen C; Wu Y; Liao Q; Zou L; Sui X; Xie T; Zhang J; Hu Y
    Adv Drug Deliv Rev; 2022 Sep; 188():114445. PubMed ID: 35820601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in nanomedicine for enhanced cancer chemotherapy.
    Wei G; Wang Y; Yang G; Wang Y; Ju R
    Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.
    Sa P; Sahoo SK; Dilnawaz F
    Curr Med Chem; 2023; 30(29):3335-3355. PubMed ID: 36154585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.